Compare ANIX & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIX | NCSM |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 127.5M |
| IPO Year | 2013 | 2017 |
| Metric | ANIX | NCSM |
|---|---|---|
| Price | $3.49 | $51.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 209.9K | 3.3K |
| Earning Date | 05-27-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 239.22 |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $142,471,000.00 |
| Revenue This Year | N/A | $5.57 |
| Revenue Next Year | N/A | $4.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.32 | $34.06 |
| 52 Week High | $5.46 | $87.36 |
| Indicator | ANIX | NCSM |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 58.29 |
| Support Level | $2.73 | $42.69 |
| Resistance Level | $3.89 | $51.69 |
| Average True Range (ATR) | 0.20 | 0.85 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 69.92 | 75.92 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.